Skip to main content
Header logo
  • About Moberg Open link menu
    About Moberg
    • CEO Comments
    • Business Model
    • Board and Leadership
  • MOB-015
  • Sustainability
  • Investors Open link menu
    Investors
    • Results and Presentations
    • The share Open link menu
      The share
      • Major shareholders
      • Insider Trading
      • Financial Data
    • Analysts
    • Calendar
    • Corporate governance Open link menu
      Corporate governance
      • Board of directors
      • Management
      • General shareholders meetings
      • Nomination committee
      • Auditors
      • Remuneration
      • Share-based incentive program
      • Articles of Association
    • Press releases
    • Prospectus
  • Media Open link menu
    Media
    • Image Archive
    • Press Releases
  • Contact
    • EN Current language English, click to switch language
    • SV Switch to Swedish
  • Please fill out this field
Close
Please fill out this field
Press Releases
Breadcrumbs
  • Home
  • Investors
  • Press Releases

Press Releases

Press Releases Regulatory Press Releases
More
Press Releases Data
2023-02-07 08:00
Moberg Pharmas Year-end report 2022
Read more
2022-11-08 08:00
Moberg Pharma's Interim report January - September 2022
Read more
2022-11-03 08:30
Moberg Pharma's nomination committee appointed
Read more
2022-08-09 08:00
Moberg Pharma's interim report January - June 2022
Read more
2022-08-04 08:00
Moberg Pharma and Padagis sign agreement for MOB-015 in Israel
Read more
2022-06-30 08:00
New number of shares and votes in Moberg Pharma AB (publ)
Read more

Pagination

  • First page
  • Previous page
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Current page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • …
  • Next page
  • Last page
Press Releases Data
2022-04-12 16:00
Notice of Annual General Meeting in Moberg Pharma AB (publ)
Read more
2022-04-12 14:30
Moberg Pharma Annual Report for 2021
Read more
2022-04-08 10:00
Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)
Read more
2022-04-08 08:00
Moberg Pharma decides on a fully guaranteed rights issue of approximately SEK 121 million
Read more
2022-03-28 08:00
European marketing authorization application for MOB-015 submitted
Read more
2022-02-08 08:00
Moberg Pharmas Year-end report 2021
Read more

Pagination

  • First page
  • Previous page
  • …
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Current page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • …
  • Next page
  • Last page
img

Moberg Pharma AB
Telephone: 08-522 307 00
Email: [email protected]

Mailing Address: 
Gustavslundsvägen 42, 167 51 Bromma
Visiting Address: 
Gustavslundsvägen 50, 167 51 Bromma

Sign up to receive our press releases and reports.

Sign up

Home
Moberg Pharma´s Interim report January - September 2024

Footer

  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Cookies
  • Copyright
  • Cookie settings
  • © Moberg Pharma AB (publ) 2026